KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 8.97%.

  • Amneal Pharmaceuticals' EBITDA Margin fell 36800.0% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 51900.0%. This contributed to the annual value of 8.92% for FY2024, which is 3900.0% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' EBITDA Margin is 8.97%, which was down 36800.0% from 15.37% recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EBITDA Margin registered a high of 15.37% during Q2 2025, and its lowest value of 35.51% during Q2 2022.
  • In the last 5 years, Amneal Pharmaceuticals' EBITDA Margin had a median value of 8.97% in 2025 and averaged 6.33%.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBITDA Margin tumbled by -480500bps in 2022, and later surged by 488800bps in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' EBITDA Margin stood at 2.08% in 2021, then skyrocketed by 184bps to 5.91% in 2022, then plummeted by -61bps to 2.3% in 2023, then skyrocketed by 351bps to 10.38% in 2024, then fell by -14bps to 8.97% in 2025.
  • Its EBITDA Margin stands at 8.97% for Q3 2025, versus 15.37% for Q2 2025 and 14.43% for Q1 2025.